{"entity":{"id":"alg-apv-527","kind":"drug","name":"ALG.APV-527","aka":[],"tldr":"ALG.APV-527 is an antibody-like protein from Aptevo Therapeutics that switches on immune cells only where it finds a marker on tumour cells. It is being tested in several kinds of solid tumour.","summary":"ALG.APV-527 is a 4-1BB x 5T4 bispecific candidate built on Aptevo Therapeutics' ADAPTIR platform. Aptevo's August 2026 filing states that it is designed to reactivate antigen-primed T cells to kill tumour cells and is being evaluated clinically in multiple solid tumour types; the filing does not state the phase.","asOf":"2026-11-04","links":[{"label":"SEC: Aptevo Therapeutics Form S-1, August 2026","url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526361103/apvo-20260821.htm"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["bispecific-antibody"],"targets":["cd137"],"drugs":[],"companies":["aptevo-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"ALG.APV-527","modality":"Bispecific antibody (4-1BB x 5T4)","mechanism":"Binds the co-stimulatory receptor 4-1BB on T cells and the tumour antigen 5T4, designed to reactivate antigen-primed T cells at the tumour, as described by Aptevo Therapeutics.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/alg-apv-527/","neighbours":{"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"target":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/"}],"company":[{"id":"aptevo-therapeutics","kind":"company","name":"Aptevo Therapeutics","route":"/companies/aptevo-therapeutics/"}]}}